Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Correction, ENDOLUNG trial. A phase 1/2 study of the Akt/mTOR inhibitor and autophagy inducer Ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with advanced/recurrent endometrial cancer (BMC Cancer, (2024), 24, 1, (876), 10.1186/s12885-024-12501-5)

  • Leary, Alexandra
  • Estévez-García, Purificación
  • Sabatier, Renaud
  • Ray-Coquard, Isabelle|||0000-0003-2472-8306
  • Romeo, Margarita|||0000-0003-1725-8115
  • Barretina-Ginesta, Maria-Pilar|||0000-0003-0074-6614
  • Gil-Martin, Marta|||0000-0002-8548-5355
  • Garralda, Elena|||0000-0002-4412-7842
  • Bosch-Barrera, J.|||0000-0002-0893-7821
  • Morán, Teresa
  • Martin-Martorell, Paloma
  • Nadal, Ernest|||0000-0002-9674-5554
  • Gascón, Pere|||0000-0001-9690-9873
  • Rodon Ahnert, Jordi|||0000-0001-6467-3632
  • Lizcano de Vega, José Miguel|||0000-0002-3154-5383
  • Muñoz-Guardiola, Pau|||0000-0002-0741-4463
  • Fierro-Durán, Gemma
  • Pedrós-Gámez, Oriol
  • Pérez-Montoyo, Hector
  • Yeste-Velasco, Marc|||0000-0001-7788-0913
  • Cortal, Marc
  • Perez Campos, Antonio
  • Alfón, José|||0000-0002-1874-0184
  • Domenech, Carles|||0000-0002-2817-3750
  • Pérez-Fidalgo, Alejandro
  • Oaknin, Ana|||0000-0002-3592-7194
Following publication of the original article [1], the authors reported the the equal contribution statement was missing in the original submission. The correct equal contribution statement is: Alejandro Pérez-Fidalgo and Ana Oaknin contributed equally to this work.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

ENDOLUNG trial. A phase 1/2 study of the Akt/mTOR inhibitor and autophagy inducer Ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with advanced/recurrent endometrial cancer

  • Leary, Alexandra
  • Estévez-García, Purificación
  • Sabatier, Renaud
  • Ray-Coquard, Isabelle|||0000-0003-2472-8306
  • Romeo, Margarita|||0000-0003-1725-8115
  • Barretina-Ginesta, Maria-Pilar|||0000-0003-0074-6614
  • Gil-Martin, Marta|||0000-0002-8548-5355
  • Garralda, Elena|||0000-0002-4412-7842
  • Bosch-Barrera, J.|||0000-0002-0893-7821
  • Morán, Teresa
  • Martin-Martorell, Paloma
  • Nadal, Ernest|||0000-0002-9674-5554
  • Gascón, Pere|||0000-0001-9690-9873
  • Rodon Ahnert, Jordi|||0000-0001-6467-3632
  • Lizcano de Vega, José Miguel|||0000-0002-3154-5383
  • Muñoz-Guardiola, Pau|||0000-0002-0741-4463
  • Fierro-Durán, Gemma
  • Pedrós-Gámez, Oriol
  • Pérez-Montoyo, Hector
  • Yeste-Velasco, Marc|||0000-0001-7788-0913
  • Cortal, Marc
  • Perez Campos, Antonio
  • Alfón, José|||0000-0002-1874-0184
  • Domenech, Carles|||0000-0002-2817-3750
  • Pérez-Fidalgo, Alejandro
  • Oaknin, Ana|||0000-0002-3592-7194
Background: Carboplatin and paclitaxel (CP) have been the standard of care for advanced/recurrent endometrial cancer (EC) for many years. However, this chemotherapy combination shows limited efficacy and recurrences often occur in less than 12 months. ABTL0812 is a novel drug that selectively kill cancer cells by cytotoxic autophagy and has shown anticancer efficacy in preclinical models of EC in combination with CP. Methods: ENDOLUNG was an open-label, phase 1/2 clinical trial designed to determine the safety and efficacy of Ibrilatazar (ABTL0812) with CP in patients with advanced/recurrent EC and non-irradiable stage III and IV squamous non-small cell lung cancer (sq-NSCLC). The phase 1 part consisted of a 3 + 3 de-escalation design followed by an expansion cohort with 12 patients. The primary endpoint was safety. ABTL0812 starting dose was 1300 mg tid combined with carboplatin at area under the curve (AUC) 5 and paclitaxel at 175 mg/m both administered every 21 days for up to 8 cycles. The phase 2 part included a total of 51 patients. The primary endpoint was overall response rate (ORR) and the secondary endpoints included duration of response (DOR), progression-free survival (PFS) and overall survival (OS). Results: During the phase 1 only one dose limiting toxicity (DLT), a grade 4 neutropenia, was observed in 1 out of 6 patients, thus no de-escalation was applied. One additional DLT, a grade 3 febrile neutropenia, was observed in the expansion cohort, thus the recommended phase 2 dose (RP2D) for ABTL0812 was established at 1300 mg tid. Most frequent hematological adverse events (AE) of the combination were neutropenia (52.9%), anemia (37.3%) and thrombocytopenia (19.6%). Nausea (66.7%), asthenia (66.7%), diarrhea (54.9%) and vomiting (54.9%) were the most frequent non-hematological adverse events (AEs). The combination of ABTL0812 plus CP showed an ORR of 65.8% (13.2% complete response and 52.6% partial response) with a median DOR of 7.4 months (95% CI: 6.3-10.8 months). Median PFS was 9.8 months (95% CI: 6.6-10.6) and median OS 23.6 months (95% CI 6.4-ND). Pharmacokinetic parameters were compatible with target engagement observed in preclinical studies, and blood pharmacodynamic biomarkers indicated sustained target regulation during, at least, 28 days after starting the treatment. Conclusions: This study suggests that the combination of ABTL0812 with CP is safe and feasible with an encouraging activity in patients with advanced/recurrent EC. Our data warrant further confirmation in prospective randomized trials. Trial registration: EU Clinical Trial Register, EudraCT number 2016-001352-21 and National Clinical Trials Number, NCT03366480. Registration on 19 September 2016.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Genetic manipulation of LKB1 elicits lethal metastatic prostate cancer

  • Hermanova, Ivana
  • Zúñiga-García, Patricia
  • Caro-Maldonado, Alfredo|||0000-0002-5431-7949
  • Fernandez-Ruiz, Sonia
  • Salvador Velez, Fernando Maria|||0000-0002-0546-1354
  • Martín-Martín, Natalia|||0000-0002-2527-429X
  • Zabala-Letona, Amaia
  • Nuñez-Olle, Marc|||0000-0002-3593-2591
  • Torrano, Verónica
  • Camacho, Laura
  • Lizcano de Vega, José Miguel|||0000-0002-3154-5383
  • Talamillo, Ana
  • Carreira, Suzanne|||0000-0002-5077-5379
  • Gurel, Bora|||0000-0002-5018-8078
  • Cortazar, Ana Rosa|||0000-0002-7082-5695
  • Guiu, Marc|||0000-0002-7083-986X
  • López, Jose I.|||0000-0003-0842-5348
  • Martinez-Romero, Anabel
  • Astobiza, Ianire|||0000-0002-7142-7066
  • Valcarcel, Lorea|||0000-0002-7309-9924
  • Lorente, Mar|||0000-0003-0982-0956
  • Arruabarrena-Aristorena, Amaia|||0000-0002-1636-3944
  • Velasco, Guillermo|||0000-0002-1994-2386
  • Gomez Muñoz, Antonio|||0000-0002-2539-016X
  • Suárez-Cabrera, Cristian|||0000-0003-1897-1596
  • Lodewijk, Iris
  • Flores, Juana M.|||0000-0002-7995-4426
  • Sutherland, James D.|||0000-0003-3229-793X
  • Barrio, Rosa|||0000-0002-9663-0669
  • de Bono, Johann S.|||0000-0002-2034-595X
  • Paramio, Jesús M.|||0000-0001-7520-3177
  • Trka, Jan|||0000-0002-9527-8608
  • Graupera, Mariona|||0000-0003-4608-4185
  • Gomis, Roger R.|||0000-0001-6473-2858
  • Carracedo, Arkaitz|||0000-0001-5957-1260
This study unravels an unprecedented murine model of lethal metastatic prostate cancer, based on the combined deletion of Pten and Lkb1. Importantly, minimal activity of LKB1 is sufficient to hamper prostate cancer cell aggressiveness, thus redefining the relationship between gene dosage and tumor suppression. Gene dosage is a key defining factor to understand cancer pathogenesis and progression, which requires the development of experimental models that aid better deconstruction of the disease. Here, we model an aggressive form of prostate cancer and show the unconventional association of LKB1 dosage to prostate tumorigenesis. Whereas loss of Lkb1 alone in the murine prostate epithelium was inconsequential for tumorigenesis, its combination with an oncogenic insult, illustrated by Pten heterozygosity, elicited lethal metastatic prostate cancer. Despite the low frequency of LKB1 deletion in patients, this event was significantly enriched in lung metastasis. Modeling the role of LKB1 in cellular systems revealed that the residual activity retained in a reported kinase-dead form, LKB1 K78I, was sufficient to hamper tumor aggressiveness and metastatic dissemination. Our data suggest that prostate cells can function normally with low activity of LKB1, whereas its complete absence influences prostate cancer pathogenesis and dissemination.